These findings indicate that modulation of the Nrf2 pathway, in conjunction with metabolic targeting, could yield promising therapeutic strategies for NSCLC patients lacking genotype-directed therapies. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.